Theravance Seeks A Way Back From Second Ampreloxetine Disappointment
With New MSA Focus
Executive Summary
The US firm’s ampreloxetine flunked a second Phase III orthostatic hypotension study but positive data in a prespecified subset have left a narrow path for a potential collaboration and approval, its CEO tells Scrip.
You may also be interested in...
Theravance To Slash Headcount By 75% After Latest Clinical Trial Setback
The Phase III failure of ampreloxetine in nOH followed disappointing Phase IIb data for izencitinib in ulcerative colitis in August. Theravance narrows focus to respiratory disease, including label expansions for Yupelri.
Theravance's Gut-Selective JAK Inhibitor Disappoints In Ulcerative Colitis Study
Top-line results from a Phase IIb study of Theravance’s potential gut-selective JAK inhibitor izencitinib have not matched expectations, and results from a similar early-stage study in Crohn’s disease with the Janssen-partnered candidate are now awaited at the end of the year or in early 2022.
Ariceum Hopes To One-Up Novartis Drug With Potent Radiopharmaceutical Focus
Emerging Company Profile: The private German biotech Ariceum has just launched with a €25m financing to advance its lead radioligand candidate, satoreotide, into Phase I development and hopes its antagonist approach could give Novartis’s Lutathera a run for its money.